Advisory Services Network LLC increased its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 0.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,565 shares of the medical research company’s stock after buying an additional 112 shares during the period. Advisory Services Network LLC’s holdings in Edwards Lifesciences Corporation were worth $1,486,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in EW. BlackRock Inc. boosted its holdings in Edwards Lifesciences Corporation by 2,184.9% during the first quarter. BlackRock Inc. now owns 14,003,695 shares of the medical research company’s stock worth $1,317,326,000 after buying an additional 13,390,818 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Edwards Lifesciences Corporation by 161.7% during the second quarter. Bank of New York Mellon Corp now owns 5,304,536 shares of the medical research company’s stock worth $627,207,000 after buying an additional 3,277,726 shares in the last quarter. Egerton Capital UK LLP purchased a new stake in Edwards Lifesciences Corporation during the second quarter worth $217,805,000. Koch Industries Inc. boosted its holdings in Edwards Lifesciences Corporation by 28,363.1% during the second quarter. Koch Industries Inc. now owns 1,397,254 shares of the medical research company’s stock worth $1,386,000 after buying an additional 1,392,345 shares in the last quarter. Finally, Marshall Wace North America L.P. purchased a new stake in Edwards Lifesciences Corporation during the first quarter worth $126,959,000. 81.90% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Corporation (NYSE EW) traded up 0.29% during midday trading on Monday, reaching $108.56. 187,030 shares of the company traded hands. The firm has a market capitalization of $22.92 billion, a PE ratio of 32.93 and a beta of 0.62. The company’s 50-day moving average price is $111.37 and its 200 day moving average price is $111.56. Edwards Lifesciences Corporation has a 12 month low of $81.12 and a 12 month high of $121.45.

Edwards Lifesciences Corporation (NYSE:EW) last announced its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The firm had revenue of $842.00 million during the quarter, compared to the consensus estimate of $839.16 million. During the same quarter in the previous year, the company posted $0.76 EPS. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.

A number of analysts recently issued reports on EW shares. BidaskClub raised shares of Edwards Lifesciences Corporation from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 22nd. Zacks Investment Research downgraded shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 26th. BMO Capital Markets restated a “buy” rating and set a $132.00 price objective on shares of Edwards Lifesciences Corporation in a research report on Friday, September 1st. Cowen and Company restated a “buy” rating and set a $135.00 price objective on shares of Edwards Lifesciences Corporation in a research report on Thursday. Finally, Barclays PLC upped their price objective on shares of Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 27th. Seven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $120.75.

ILLEGAL ACTIVITY NOTICE: This report was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://theolympiareport.com/2017/10/16/edwards-lifesciences-corporation-ew-position-increased-by-advisory-services-network-llc.html.

In related news, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $114.80, for a total value of $3,776,920.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $108.86, for a total transaction of $576,958.00. The disclosure for this sale can be found here. Insiders sold a total of 182,201 shares of company stock valued at $20,768,154 in the last three months. 2.13% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.